Introduction

Jagsonpal Pharma Share Price Target 2025 Screener History is a topic of keen interest for investors and analysts tracking the Indian pharmaceutical sector. Jagsonpal Pharmaceuticals Ltd, a mid-cap pharma company listed on the NSE and BSE, has garnered investor attention for its consistent performance in the generic medicine segment. With the ever-growing demand for healthcare and pharmaceuticals in India and across the globe, pharmaceutical companies like Jagsonpal are strategically positioned to leverage this momentum. In this article, we will dive into the current share price of Jagsonpal Pharma, its projected share price target for 2025, its detailed performance metrics available on financial screeners, and its historical stock movement. By understanding each of these aspects, investors can make more informed decisions. Whether you are a long-term investor, a short-term trader, or someone curious about the pharma industry’s performance on the stock market, this guide offers comprehensive insights.

Jagsonpal Pharma Share Price

Jagsonpal Pharma Share Price has been a topic of observation due to the company’s solid fundamentals and promising product pipeline. As of the latest available data in 2025, Jagsonpal’s share is trading around ₹300–₹350 on the NSE. This valuation reflects market confidence in its continued earnings growth and strategic expansions. Over the past year, the stock has shown a steady uptrend, driven by positive quarterly results and growing investor interest in pharma and healthcare stocks.

The company primarily focuses on manufacturing and marketing branded generic pharmaceutical products. Its portfolio includes drugs in therapeutic categories such as orthopedics, gynecology, and pain management. Jagsonpal’s increasing focus on quality manufacturing, coupled with a distribution network that reaches across India, helps stabilize its revenue streams.

Furthermore, institutional holdings have shown mild upticks, reflecting growing faith from mutual funds and other long-term investors. While the stock is not as volatile as high-beta tech stocks, it offers a relatively stable performance, making it appealing to conservative investors.

Jagsonpal Pharma Share Price Target 2025

Jagsonpal Pharma Share Price Target 2025 is being closely watched by analysts and retail investors alike. Based on technical chart patterns, fundamental analysis, and projected earnings growth, many financial analysts suggest a potential price target in the range of ₹450 to ₹550 by the end of 2025. This projection represents a potential upside of 30–60% from its current levels, assuming the market conditions remain favorable.

Several factors contribute to this bullish forecast. The Indian pharmaceutical sector is projected to expand at a compound annual growth rate (CAGR) exceeding 10% through 2030. Within this rapidly growing market, Jagsonpal Pharma is strategically enhancing its manufacturing scale, boosting operational margins, and diversifying its therapeutic product range—factors likely to contribute to strong financial growth.

Investors looking at 2025 as a medium-term horizon should consider factors like earnings per share (EPS) growth, return on equity (ROE), and debt-to-equity ratio. As of now, Jagsonpal maintains a healthy balance sheet with manageable debt and consistent profit margins. These fundamentals, along with a stable macroeconomic backdrop, are likely to push the share price toward the forecasted target range.

Jagsonpal Pharma Share Price Screener

Jagsonpal Pharma Share Price Screener metrics provide essential financial insights for evaluating the stock’s current valuation and investment potential. On platforms like Screener.in, investors can access detailed data including PE ratio, ROCE, ROE, market capitalization, and quarterly financial results.

As per the latest Screener data:

• Market Cap: ₹800–₹1,000 crore
• Price to Earnings (PE) Ratio: Approximately 25–30
• Return on Capital Employed (ROCE): Around 18%
• Debt to Equity: Less than 0.2, indicating low leverage
• Promoter Holding: Around 45–50%, showcasing promoter confidence

According to screener data, Jagsonpal has demonstrated continuous year-on-year revenue growth. It also maintains stable operating margins in the 15%–20% range, underscoring its ability to operate efficiently in a highly competitive industry.

Moreover, the screener allows you to track quarterly performance, where Jagsonpal has shown revenue stability even in fluctuating market conditions. Investors can also analyze peer comparisons to see how Jagsonpal fares against similar-sized pharma firms in the Indian market.

Jagsonpal Pharma Share Price History

Jagsonpal Pharma Share Price History illustrates a journey of gradual but steady growth. The stock, which was once trading below ₹100 per share in 2020, has shown consistent upward movement over the last five years. In 2021–2022, the stock entered a consolidation phase before breaking out in 2023 with renewed investor interest, owing to improved financial results and industry tailwinds.

In 2024, Jagsonpal Pharma’s share price experienced a notable surge, surpassing ₹300 after quarterly results outperformed market forecasts. This strong performance reflects the company’s resilience and long-term growth potential. Some of the most significant milestones in its price trajectory include:

• 2020: Covid-19 pandemic impact, trading below ₹80
• 2021–2022: Post-pandemic recovery, range-bound between ₹100–₹150
• 2023: Bullish breakout, reaching ₹250–₹300 range
• As the stock stabilizes through 2024 and into 2025, analysts maintain a bullish outlook with targets set beyond ₹500.

By studying the stock's price history, long-term investors can understand its market behavior, resistance levels, and growth trajectory. Historical performance often serves as a baseline for forecasting future trends, especially when supported by fundamental improvements.

Conclusion

In conclusion, the Jagsonpal Pharma Share Price Target 2025 Screener History paints a promising picture for potential investors. The stock’s current price shows resilience and upward momentum, backed by sound fundamentals and industry demand. The 2025 target range of ₹450 to ₹550 reflects strong growth expectations, particularly if Jagsonpal continues to expand its market reach and maintain profitability. Financial screener metrics confirm the company’s operational strength and low-risk profile, while its historical performance showcases its ability to navigate market volatility.

Investors seeking a balanced, mid-cap pharmaceutical stock for medium to long-term investment should consider Jagsonpal as a viable option. However, as with all equity investments, it is advisable to conduct personal due diligence or consult a financial advisor before taking positions. Jagsonpal Pharma, with its sustained business model and sector positioning, could be a valuable addition to a diversified investment portfolio aiming for growth in the healthcare segment.